<DOC>
	<DOC>NCT00255476</DOC>
	<brief_summary>The purpose of this study is to compare the objectie tumour response rate between the cisplatin/5FU and cisplatin/5FU plus ZD1839 combination</brief_summary>
	<brief_title>The IRESSA Novel Head and Neck Chemotherapy Evaluation Study</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms, Squamous Cell</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Provision of written informed consent Patients with histologically proven primary SCCHN Aged 18 or over Patients eligible for surgery with curative intent Other coexisting malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ Exclude UCNT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>